Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis

Abstract excerpt

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR). Newly developed "correctors" such as lumacaftor (VX-809) that improve CFTR maturation and trafficking and "potentiators" such as ivacaftor (VX-770) that enhance channel activity may provide important advances in CF therapy. Although VX-770 has demonstrated substantial clinical efficacy in the small subset of patients...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Asthma and respiratory diseases
• Share to Cystic Fibrosis Research Advances